vs
ALLURION TECHNOLOGIES, INC.（ALUR）与ARTIVION, INC.（AORT）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是ALLURION TECHNOLOGIES, INC.的32.1倍（$116.0M vs $3.6M）。ARTIVION, INC.净利率更高（2.1% vs -167.0%，领先169.1%）。ARTIVION, INC.同比增速更快（19.2% vs -35.4%）。过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -38.0%）
罗宾逊科技是一家日本电子游戏开发商，由塞思·罗宾逊创立。该公司开发了《赤龙传说》、《行星：太空探索》等BBS门户游戏，还与Hamumu Software合作开发了实验性多人创意沙盒游戏《成长国度》，该作于2013年在iOS、安卓、Windows和macOS平台推出。
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
ALUR vs AORT — 直观对比
营收规模更大
AORT
是对方的32.1倍
$3.6M
营收增速更快
AORT
高出54.6%
-35.4%
净利率更高
AORT
高出169.1%
-167.0%
两年增速更快
AORT
近两年复合增速
-38.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6M | $116.0M |
| 净利润 | $-6.0M | $2.4M |
| 毛利率 | 44.5% | 63.1% |
| 营业利润率 | -174.2% | 9.2% |
| 净利率 | -167.0% | 2.1% |
| 营收同比 | -35.4% | 19.2% |
| 净利润同比 | 37.2% | 114.7% |
| 每股收益（稀释后） | $-0.69 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALURAORT
| Q4 25 | $3.6M | $116.0M | ||
| Q3 25 | $2.7M | $113.4M | ||
| Q2 25 | $3.4M | $113.0M | ||
| Q1 25 | $5.6M | $99.0M | ||
| Q4 24 | $5.6M | $97.3M | ||
| Q3 24 | $5.4M | $95.8M | ||
| Q2 24 | $11.8M | $98.0M | ||
| Q1 24 | $9.4M | $97.4M |
净利润ALURAORT
| Q4 25 | $-6.0M | $2.4M | ||
| Q3 25 | $-11.9M | $6.5M | ||
| Q2 25 | $-9.3M | $1.3M | ||
| Q1 25 | $-1.5M | $-505.0K | ||
| Q4 24 | $-9.6M | $-16.5M | ||
| Q3 24 | $8.7M | $-2.3M | ||
| Q2 24 | $-8.3M | $-2.1M | ||
| Q1 24 | $2.0M | $7.5M |
毛利率ALURAORT
| Q4 25 | 44.5% | 63.1% | ||
| Q3 25 | 49.1% | 65.6% | ||
| Q2 25 | 73.9% | 64.7% | ||
| Q1 25 | 74.6% | 64.2% | ||
| Q4 24 | 45.3% | 63.2% | ||
| Q3 24 | 58.0% | 63.7% | ||
| Q2 24 | 76.4% | 64.6% | ||
| Q1 24 | 73.2% | 64.6% |
营业利润率ALURAORT
| Q4 25 | -174.2% | 9.2% | ||
| Q3 25 | -362.3% | 11.1% | ||
| Q2 25 | -205.7% | 7.4% | ||
| Q1 25 | -130.5% | 2.2% | ||
| Q4 24 | -306.2% | 2.7% | ||
| Q3 24 | -229.9% | 4.6% | ||
| Q2 24 | -79.4% | 6.6% | ||
| Q1 24 | -121.4% | 26.0% |
净利率ALURAORT
| Q4 25 | -167.0% | 2.1% | ||
| Q3 25 | -447.1% | 5.7% | ||
| Q2 25 | -276.3% | 1.2% | ||
| Q1 25 | -26.9% | -0.5% | ||
| Q4 24 | -171.8% | -16.9% | ||
| Q3 24 | 162.8% | -2.4% | ||
| Q2 24 | -70.7% | -2.2% | ||
| Q1 24 | 21.3% | 7.7% |
每股收益（稀释后）ALURAORT
| Q4 25 | $-0.69 | $0.06 | ||
| Q3 25 | $-1.53 | $0.13 | ||
| Q2 25 | $-1.28 | $0.03 | ||
| Q1 25 | $-0.31 | $-0.01 | ||
| Q4 24 | $-3.22 | $-0.40 | ||
| Q3 24 | $3.40 | $-0.05 | ||
| Q2 24 | $-4.34 | $-0.05 | ||
| Q1 24 | $0.96 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.4M | $64.9M |
| 总债务越低越好 | — | $215.1M |
| 股东权益账面价值 | $-77.2M | $448.2M |
| 总资产 | $15.8M | $884.8M |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资ALURAORT
| Q4 25 | $5.4M | $64.9M | ||
| Q3 25 | $6.1M | $73.4M | ||
| Q2 25 | $12.7M | $53.5M | ||
| Q1 25 | $20.4M | $37.7M | ||
| Q4 24 | $15.4M | $53.5M | ||
| Q3 24 | $28.7M | $56.2M | ||
| Q2 24 | $19.3M | $55.0M | ||
| Q1 24 | $29.7M | $51.1M |
总债务ALURAORT
| Q4 25 | — | $215.1M | ||
| Q3 25 | — | $214.9M | ||
| Q2 25 | — | $215.6M | ||
| Q1 25 | — | $314.7M | ||
| Q4 24 | — | $314.3M | ||
| Q3 24 | — | $314.0M | ||
| Q2 24 | — | $313.6M | ||
| Q1 24 | — | $313.3M |
股东权益ALURAORT
| Q4 25 | $-77.2M | $448.2M | ||
| Q3 25 | $-82.9M | $438.7M | ||
| Q2 25 | $-64.0M | $419.9M | ||
| Q1 25 | $-69.8M | $294.3M | ||
| Q4 24 | $-78.0M | $276.2M | ||
| Q3 24 | $-64.8M | $304.7M | ||
| Q2 24 | $-70.6M | $295.1M | ||
| Q1 24 | $-66.2M | $295.0M |
总资产ALURAORT
| Q4 25 | $15.8M | $884.8M | ||
| Q3 25 | $18.1M | $857.7M | ||
| Q2 25 | $28.2M | $838.4M | ||
| Q1 25 | $38.4M | $791.2M | ||
| Q4 24 | $32.8M | $789.1M | ||
| Q3 24 | $50.7M | $803.1M | ||
| Q2 24 | $46.5M | $789.5M | ||
| Q1 24 | $60.0M | $784.0M |
负债/权益比ALURAORT
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.06× | ||
| Q1 24 | — | 1.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $19.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.9M |
| 自由现金流率自由现金流/营收 | — | -6.9% |
| 资本支出强度资本支出/营收 | — | 23.7% |
| 现金转化率经营现金流/净利润 | — | 8.06× |
| 过去12个月自由现金流最近4个季度 | — | $839.0K |
8季度趋势，按日历期对齐
经营现金流ALURAORT
| Q4 25 | $-5.3M | $19.6M | ||
| Q3 25 | $-6.5M | $22.3M | ||
| Q2 25 | $-7.6M | $15.0M | ||
| Q1 25 | $-9.5M | $-17.0M | ||
| Q4 24 | $-13.3M | $10.1M | ||
| Q3 24 | $-11.5M | $11.5M | ||
| Q2 24 | $-8.9M | $6.1M | ||
| Q1 24 | $-8.6M | $-5.5M |
自由现金流ALURAORT
| Q4 25 | — | $-7.9M | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $11.7M | ||
| Q1 25 | — | $-20.6M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | $-11.5M | $7.8M | ||
| Q2 24 | $-9.4M | $3.6M | ||
| Q1 24 | $-8.7M | $-9.1M |
自由现金流率ALURAORT
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | 10.4% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | -214.9% | 8.2% | ||
| Q2 24 | -79.6% | 3.7% | ||
| Q1 24 | -93.1% | -9.3% |
资本支出强度ALURAORT
| Q4 25 | — | 23.7% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | 0.0% | 1.5% | ||
| Q3 24 | 1.3% | 3.8% | ||
| Q2 24 | 3.7% | 2.6% | ||
| Q1 24 | 1.1% | 3.7% |
现金转化率ALURAORT
| Q4 25 | — | 8.06× | ||
| Q3 25 | — | 3.42× | ||
| Q2 25 | — | 11.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4.33× | -0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALUR
暂无分部数据
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
